A Comparison of Vancomycin and Metronidazole for the Treatment of Clostridium difficile-associated Diarrhea (CDAD) in Medical Intensive Care Unit (MICU).
10.24304/kjcp.2017.27.2.77
- Author:
Eun Ae CHO
1
;
Kyung A LEE
;
Jae Song KIM
;
Soo Hyun KIM
;
Eun Sun SON
Author Information
1. Department of Pharmacy, Yonsei University Health System, Seoul 03722, Republic of Korea. sespharm@yuhs.ac
- Publication Type:Practice Guideline ; Original Article
- Keywords:
Clostridium difficile associated diarrhea;
metronidazole;
vancomycin;
medical intensive care unit (micu)
- MeSH:
Anti-Bacterial Agents;
Clostridium difficile;
Clostridium*;
Critical Care*;
Diarrhea*;
Gastroenterology;
Humans;
Immunosuppression;
Inpatients;
Intensive Care Units*;
Metronidazole*;
Recurrence;
Retrospective Studies;
Risk Factors;
Ulcer;
Vancomycin*
- From:Korean Journal of Clinical Pharmacy
2017;27(2):77-82
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Clostridium difficile associated diarrhea (CDAD) is a leading cause of hospital-associated gastrointestinal illness. Risk factors for CDAD include advanced age, long-term admission, antibiotics, proton-pump inhibitor or H₂ blocker use and immunosuppression. The practice guideline of American Journal of Gastroenterology (2013) suggests metronidazole for the first-line therapy of mild-moderate CDAD as well as vancomycin for severe CDAD. MICU inpatients receiving stress ulcer prophylaxis and antibiotics are susceptible to nosocomial CDAD. Therefore, this study aimed to evaluate occurrence and treatment of CDAD in MICU. METHODS: Patients who were admitted to the MICU and had CDAD from August 2012 to August 2015 were analyzed retrospectively. RESULTS: Of the 90 patients with CDAD, 20 patients (2.22%) had mild-moderate CDAD (16 received metronidazole and 4 received vancomycin therapy) and 70 patients (77.8%) had severe CDAD(54 received metronidazole and 16 received vancomycin therapy). Among the patients with mild-moderate CDAD, treatment with metronidazole or vancomycin resulted in same clinical cure in 50% of the patients (p=1.00). Among the patients with severe CDAD, treatment with metronidazole or vancomycin resulted in clinical cure in 40.7% and 50.0% of the patients, respectively (p=0.511). Clinical symptoms recurred in 7.4% of the severe CDAD patients treated with metronidazole and 6.3% of those treated with vancomycin (p=0.875). CONCLUSION: Our findings suggest that metronidazole and vancomycin are equally effective for the treatment of mild-moderate CDAD; however, vancomycin demonstrated higher clinical cure rate and lower recurrence rate for severe CDAD, although the difference was not statistically significant. For better clinical outcomes, appropriate medication use by disease severity is needed.
